Background Worldwide, although predominantly in low-income countries in the Middle East and Africa, up to 13% of hepatitis C virus (HCV) infections are caused by HCV genotype 4. For patients with HCV genotype 1, the combination of ledipasvir and sofosbuvir has been shown to cure high proportions of patients with excellent tolerability, but this regimen has not been assessed for the treatment of HCV genotype 4. We assessed the effi cacy, safety, and tolerability of 12 weeks of combination therapy with ledipasvir and sofosbuvir for patients with chronic HCV genotype 4 infections.
Introduction
Roughly 185 million people worldwide are infected with hepatitis C virus (HCV), which is associated with progression to end-stage liver disease and hepatocellular carcinoma.
1,2 HCV genotype 4 accounts for about 8-13% of these infections, mainly concentrated in sub-Saharan Africa, northern Africa, the Middle East, and southeast Asia. 3, 4 Within Europe, HCV genotype 4 is present in a substantial proportion of patients with HCV infections in countries including Belgium, France, and Greece. 5 In Egypt, genotype 4 HCV is particularly common, and about 15% of the Egyptian population is infected with this subtype. 3 Although the development of ribavirin-free and interferon-free regimens for HCV genotype 1 has progressed rapidly, simple well tolerated treatments for HCV genotype 4 are particularly crucial in view of the high concentration of this genotype in low-income countries, where laboratory monitoring for adverse events might not be feasible. 4 In 2014, the directly acting antivirals sofosbuvir and simeprevir were introduced. Sofosbuvir or simeprevir in combination with pegylated interferon and ribavirin for 12 weeks substantially improved the proportion of patients with HCV genotype 4 achieving a sustained viral response (SVR). 6 For patients who were ineligible for interferon treatment, sofosbuvir and ribavirin for 24 weeks was also recommended. 6 Although these regimens are associated with high 59-100% SVR for patients who are treatment naive or treatment experienced, they include multiple pills, injections, and long treatment durations. 6 Additionally, both interferon and ribavirin need frequent laboratory monitoring and are associated with toxic eff ects, including fatigue, anaemia, and teratogenicity.
Two directly acting antivirals, ledipasvir (an NS5A inhibitor) and sofosbuvir (a nucleotide polymerase inhibitor), have been approved in the USA for combination use for the treatment of HCV genotype 1. Results from studies of this combination, given as one pill per day for 12 weeks, have shown 91-100% SVR in patients with HCV genotype 1 who are treatment naive and treatment experienced, with few adverse events. 7, 8 In vitro, both ledipasvir and sofosbuvir have anti-HCV activity against HCV genotype 4 that is similar to that noted against HCV genotype 1. However, the clinical effi cacy of this regimen in vivo for HCV genotype 4 has not yet been established.
Historically, proportions of patients with HCV genotype 4 who achieve SVR when given interferoncontaining treatments have been between those of patients with HCV genotype 1 and HCV genotypes 2 and 3.
9,10 Furthermore, the in-vitro effi cacy of ledipasvir and sofosbuvir for HCV genotype 4 suggests that the combination of these potent directly acting antivirals without ribavirin for 12 weeks might be eff ective for the treatment of HCV genotype 4 in patients who are treatment naive or interferon treatment experienced. Therefore, we did a clinical trial to assess the two drug combination of ledipasvir and sofosbuvir for 12 weeks for the treatment of patients with HCV genotype 4.
Methods

Study design
In this single-centre, open-label cohort, non-randomised phase 2a trial, we sequentially enrolled patients with HCV genotype 4 at the Clinical Center of the National Institutes of Health, Bethesda, MD, USA. The study was approved by the Institutional Review Board of the National Institute of Allergy and Infectious Diseases (NIAID) and was done in compliance with the Good Clinical Practice guidelines, the Declaration of Helsinki, and regulatory requirements. The Regulatory Compliance and Human Participants Protection Branch of NIAID served as the study sponsor and medical monitor. Gilead Sciences provided drug and scientifi c advice.
Patients
Eligible participants were men and women, aged 18 years or older, with chronic HCV genotype 4 infection (serum HCV RNA ≥2000 IU/mL) and compensated liver disease, and who were treatment naive or treatment experi enced (previous exposure to directly acting antivirals was exclusionary). We excluded patients with HIV or hepatitis B virus infection. We invited all eligible patients at the study centre to enrol. We contacted patients for screening visits in the order in which they initially contacted the study team for participation and enrolled them in the order in which they completed screening requirements. We measured the stage of liver disease by liver biopsy or a Fibrosure test. We did not use Fibroscan because of its low availability at most medical care centres in the USA at the time of study initiation. The appendix includes full eligibility criteria. We obtained written or oral informed consent from all participants.
Procedures
We gave patients 90 mg ledipasvir and 400 mg sofosbuvir as a single combination tablet once per day for 12 weeks. We stopped giving study drugs if patients did not achieve more than a 2 log 10 reduction in HCV RNA by week 4, unless a 2 log 10 or more reduction would be less than the lower limit of HCV quantifi cation. We included all patients who took at least one pill in the fi nal analysis. In accordance with the protocol, if participants failed treatment, they were off ered treatment with the standard of care, which at the time of the study was pegylated interferon and ribavirin or ribavirin alone with sofosbuvir. Neither patients nor investigators were masked to treatment allocation.
We measured plasma HCV RNA concentrations using the RealTime HCV Assay (Abbott, Chicago, IL, USA), with a lower limit of quantifi cation of 12 IU/mL and a
Research in context
Systematic review
We searched PubMed on Feb 11, 2015, for articles published between Jan 1, 2000, and Feb 11, 2015, using a combination of the MeSH search terms "HCV treatment", "antiviral agent", and "genotype 4" and consulted the hepatitis C virus (HCV) treatment guidelines for phase 2 or 3 clinical trials of treatments for patients with HCV genotype 4. We also searched the reference lists of articles from our search for additional reports that met our inclusion criteria of phase 2 and phase 3 clinical trials of interferon-free regimens for treatment of HCV genotype 4.
Four clinical trials have been reported (one journal article and four in abstract form) for interferon-free regimens for patients with HCV genotype 4. The results of these trials have shown promising safety and effi cacy (sustained viral response at 12 weeks, 84-100%) with combination direct-acting antiviral drugs, with or without ribavirin for 12-24 weeks. Few patients with cirrhosis or who have previously been treated with interferon-containing regimens have been included.
Added value of this study
Although our study is small, we showed high rates of sustained viral response at 12 weeks with use of sofosbuvir and ledipasvir for 12 weeks, which supports the possibility that this simple regimen might be eff ective for some patients.
Implications of all the available evidence
Further development of this effi cacious, simple, well tolerated regimen is warranted and studies in patients with cirrhosis and previously treated patients should be pursued.
See Online for appendix lower limit of detection of 3 IU/mL, at the start of the study; weeks 4, 8, and 12 of treatment; and 2, 4, 8, and 12 weeks after treatment. We also measured serum HCV RNA levels with the COBAS TaqMan HCV RNA assay, version 1.0 (Roche, Pleasanton, CA, USA), with a lower limit of quantifi cation of 43 IU/mL and a lower limit of detection of 15 IU/mL at screening, day 0 and weeks 4, 8, 12, 36, 48, and 60.
We recorded adverse events and clinical laboratory results throughout the study. We graded adverse events from grade 1 (mild) to grade 4 (severe) in accordance with the NIAID Division of AIDS (DAIDS) toxicity table (version 1.0).
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Outcomes
The primary effi cacy outcome was SVR12, defi ned as the proportion of participants with plasma HCV viral load less than the lower limit of quantifi cation of the Roche COBAS TaqMan HCV RNA assay 12 weeks after treatment completion. The lower limit of quantifi cation is the lowest HCV RNA concentration that is within the linear range of detection of the HCV RNA assay.
The primary safety outcome was the frequency and severity of adverse events. Secondary outcomes that we completed and included in this study are the proportion of participants with unquantifi able HCV viral load at specifi ed timepoints during and after treatment, treatment discontinuations, adverse events, and safety laboratory changes. Data up to and including SVR12 are reported in this study and follow-up for 48 weeks posttreatment is ongoing.
Statistical analysis
The primary effi cacy and safety analyses were based on an intention-to-treat population (all patients who received at least one dose of study drugs). We calculated the sample size to provide both a suffi ciently high probability of identifi cation of at least one adverse event of probability 10% or more and with prespecifi ed CIs for estimates of effi cacy, assuming 20 patients. Because one patient dropped out at week 5 and was replaced, we calculated post-hoc CIs for 21 patients. With 21 patients in the treatment group, if the true probability of an adverse event caused by a regimen is 10% or more, a sample size of 21 provides an 88% chance of identifi cation of at least one such adverse event. With a sample size of 21, if all patients achieved SVR12, the 95% CI for that estimate is 87-100 and if 19 patients achieved SVR12, the 95% CI for that estimate would be 76-100. We calculated the proportion of patients achieving SVR12 after completion of therapy. We did analyses with PRISM 6.0. This study is registered with ClinicalTrials.gov, number NCT01805882.
Role of the funding source
Data collection, review, and analysis were done by NIH and University of Maryland investigators. AK and SK participated in the study design and all authors contributed to the writing of the report. NIH and University of Maryland-affi liated investigators (AK, RK, ZS, AN, SS, RS, CK, CG, MAP, HM, and SK) had full access to all data in the study, and AK and the corresponding author had fi nal responsibility for the decision to submit for publication.
The Regulatory Compliance and Human Participants Protection Branch of the National Institute of Allergy and Infectious Diseases (NIAID) served as the study sponsor and were involved in the review and approval of the study via the usual peer-review process as well as the study management. They did not have a role in the design of the study, data collection and analysis, inter pretation of the data, preparation, review, or approval of the manuscript, or the decision to submit the manuscript for publication.
Results
We enrolled and followed up patients from Sept 16, 2013, to Nov 2, 2014. We screened 24 participants and 21 were enrolled in study (fi gure). Table 1 shows baseline characteristics of the study population.
20 (95%, 95% CI 76-100) of 21 patients treated with ledipasvir and sofosbuvir achieved SVR12, in accordance with our predefi ned criteria. One patient had an HCV RNA concentration of 1 533 291 IU/mL at week 4. On further questioning the patient reported taking only one dose of study drug by week 4. This patient withdrew from the study at week 5, but is included in the intention-totreat analysis. In accordance with the protocol, we replaced this patient, but included all 21 patients in the analysis.
20 (95%) of 21 participants treated with ledipasvir and sofosbuvir had concentrations of HCV RNA that were less than the lower limit of quantifi cation by both week 4 (table 3) . Most adverse events were mild in severity. No deaths, serious adverse events, or grade 3 or 4 adverse events occurred. We identifi ed fi ve grade 3 laboratory abnormalities: decreased absolute neutrophil count in a patient who reported taking only one dose of study medication 4 weeks before we detected this eff ect; hyperglycaemia in two patients with type 2 diabetes mellitus and haemoglobin A 1C fractions of 7·6% and 8·7%, respectively, at screening; hypo phos phataemia in a patient with a history of grade 3 hypo phosphataemia before starting study drugs; and thrombocytopenia (41 000 cells per mL) in a patient with cirrhosis and thrombocytopenia (45 000 cells per mL) before starting study drugs.
Discussion
In the present study, treatment with sofosbuvir and ledipasvir for 12 weeks resulted in 95% SVR12 in patients with chronic HCV genotype 4 infections who were treatment naive or interferon treatment experienced. The regimen was well tolerated, rapidly suppressed HCV viraemia, and substantially simplifi ed treatment for HCV genotype 4. 100% of patients who received the full 12 weeks of therapy achieved SVR12.
Treatment for HCV infection is changing rapidly. 9 Results from early studies showed that sofosbuvir or simeprevir could be used in combination with pegylated interferon and ribavirin for the treatment of HCV genotype 4 infection. Subsequently, sofosbuvir and ribavirin alone for 12-24 weeks was shown to result in 59-100% SVR in patients with HCV genotype 4 who were treatment naive and treatment experienced, 14 with similar results in HIV/HCV genotype-4-co-infected patients. 15 In the PEARL-1 trial, 16 paritaprevir and ombitasvir, with or without ribavirin, were assessed in Data are mean (SD) or n (%). *Ethnic origin was self-reported. †14 patients had liver biopsies and seven patients had Fibrosure tests to stage liver disease (Fibrosure F0-F2, <0·44 cutoff with 76% sensitivity and 70% specifi city; F3, >0·60 cutoff with 47% sensitivity and 90% specifi city; F4, >0·75 cutoff with 50% sensitivity and 93% specifi city). 12,13 Data are n (%, 95% CI). The limit of HCV RNA quantifi cation was 43 IU/mL. Although many interferon-free and ribavirin-free regimens are in development for HCV genotype 1, develop ment of interferon-free and ribavirin-free regimens for HCV genotype 4 has been slow. In our proof-ofconcept study, the use of ledipasvir and sofosbuvir to treat HCV genotype 4 in mainly immigrant patients who were treatment naive and treatment experienced resulted in a high proportion of patients being cured, similar to or exceeding those of the standard of care, 14, 16, 17 with excellent tolerability. More than half of patients had a high baseline viral load, were treatment experienced, or had advanced stage 3 or 4 liver disease-factors previously associated with treatment failure in HCV genotype 1 patients. 18, 19 Despite lower EC 50 values in in-vitro replicons for ledipasvir against HCV genotype 4 (0·39 nM for genotype 4 vs 0·031 nM against genotype 1a and 0·004 nM against genotype 1b), 100% of patients who completed therapy achieved SVR, thus supporting the potency of NS5A inhibitors. 20 Although 12 weeks of therapy was eff ective in all patients who completed it, one patient in this trial was non-adherent to the study drugs and discontinued the study at week 7. The patient was treatment naive and had stage 1-2 liver disease.
Pending validation by larger trials, the results of our study suggest that the use of 12 weeks of ledipasvir and sofosbuvir is eff ective for the treatment of HCV genotype 4. A safe and simple, single-pill regimen will be ideal to treat large numbers of patients and therefore aff ect the global hepatitis genotype 4 epidemic. Whether thera peutic regimens could be shortened further for patients with specifi c host or viral parameters and comorbidities remains to be established. Further reductions in treatment duration could decrease the costs of treatment, which are high. 21 Additionally, licensing agreements in some low-income countries might also allow for further reductions in drug prices. 22 Limitations of the study include the sequential, nonrandomised enrolment, which we chose because of the toxic eff ects and low SVR associated with the standard of care at time of study initiation (pegylated interferon and ribavirin), 23 which would have been the comparator arm. Additionally, this was a single-site trial, which we deemed to be suffi cient in view of the exploratory nature of this study. Confi dence in the estimates of effi cacy is limited by the small numbers of patients included and the ability to use only historical comparisons for effi cacy. We included patients with and without cirrhosis and those who were treatment naive and treatment experienced, but the study was not powered to compare these groups. Most patients had early stage liver fi brosis (less than stage 3); other studies suggest that these patients might have more favourable responses to directly acting antiviral treatment compared with patients with advanced liver fi brosis (stage 3 or cirrhosis). 19 Further studies in patients with advanced stage 3 or 4 liver disease should be done. Although IL28B genotype has not been shown to be a useful predictor of treatment outcome for sofosbuvir and ledipasvir when used to treat HCV genotype 1, 8 we did not examine this factor in our study of HCV genotype 4. Additionally, patients received intensive nursing support and monitoring, which might not be replicable in communitybased treatment programmes for hepatitis C.
In conclusion, 12 week regimens of oral combination directly acting antiviral treatments with ledipasvir and sofosbuvir seem to be eff ective in the treatment of patients with HCV genotype 4. This simple, well tolerated treatment for HCV genotype 4 holds promise to substantially improve and simplify the treatment of HCV in the low-resource countries where this virus genotype is concentrated.
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